Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab
Objective. To reveal changes of CD+CD25+FoxP3+ T-regulatory cells (T-reg) number in pts with systemic lupus erythematosus (SLE) receiving rituximab and to assess relationship T reg content with changes of disease activity and serum autoantibodies level during treatment. Material and methods. 12 pts...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2009-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/590 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839568514543779840 |
|---|---|
| author | A V Torgashina |
| author_facet | A V Torgashina |
| author_sort | A V Torgashina |
| collection | DOAJ |
| description | Objective. To reveal changes of CD+CD25+FoxP3+ T-regulatory cells (T-reg) number in pts with systemic lupus erythematosus (SLE) receiving rituximab and to assess relationship T reg content with changes of disease activity and serum autoantibodies level during treatment. Material and methods. 12 pts with definite SLE were included. Pts were examined before treatment, after 1, 3 and 6 months. Besides routine laboratory tests anti-double-stranded DNA antibodies, B lymphocytes and T reg cells number was evaluated with flow-cytometry. SLE activity was assessed with SLEDAI 2K scale. Rituximab 500 mg was administered every week iv during 4 weeks. 4 pts received combined treatment with cyclophosphan. Results. Mean age of pts was 30,5±9,8 years (Me 31 years, varied from 18 to 49 years), disease duration varied from 7 to 148 months. T reg number before treatment was not decreased and did not correlated with anti-DNA antibodies level. T reg markers (Foxp3+, CD25+, CD4+CD25+) changes and values of SLE activity on SLEDAI 2K after the end of treatment correlated with presence of clinical response to treatment with rituximab in 3 months. Binary logistic regression model including 4 above mentioned predictors in total allows predicting correctly clinical response to therapy in 83% of cases. Conclusion. Changes of CD25+, CD4+CD25+, CD4+CD25+FoxP3+ T-cells number immediately after the end of treatment with rituximab correlated with clinical effect of the treatment and determined subsequent response to anti-B cell therapy. |
| format | Article |
| id | doaj-art-3ee726a434b34b9b86941347f682e13a |
| institution | Matheson Library |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2009-04-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-3ee726a434b34b9b86941347f682e13a2025-08-04T17:03:51ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922009-04-014723910.14412/1995-4484-2009-452530Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximabA V TorgashinaObjective. To reveal changes of CD+CD25+FoxP3+ T-regulatory cells (T-reg) number in pts with systemic lupus erythematosus (SLE) receiving rituximab and to assess relationship T reg content with changes of disease activity and serum autoantibodies level during treatment. Material and methods. 12 pts with definite SLE were included. Pts were examined before treatment, after 1, 3 and 6 months. Besides routine laboratory tests anti-double-stranded DNA antibodies, B lymphocytes and T reg cells number was evaluated with flow-cytometry. SLE activity was assessed with SLEDAI 2K scale. Rituximab 500 mg was administered every week iv during 4 weeks. 4 pts received combined treatment with cyclophosphan. Results. Mean age of pts was 30,5±9,8 years (Me 31 years, varied from 18 to 49 years), disease duration varied from 7 to 148 months. T reg number before treatment was not decreased and did not correlated with anti-DNA antibodies level. T reg markers (Foxp3+, CD25+, CD4+CD25+) changes and values of SLE activity on SLEDAI 2K after the end of treatment correlated with presence of clinical response to treatment with rituximab in 3 months. Binary logistic regression model including 4 above mentioned predictors in total allows predicting correctly clinical response to therapy in 83% of cases. Conclusion. Changes of CD25+, CD4+CD25+, CD4+CD25+FoxP3+ T-cells number immediately after the end of treatment with rituximab correlated with clinical effect of the treatment and determined subsequent response to anti-B cell therapy.https://rsp.mediar-press.net/rsp/article/view/590systemic lupus erythematosusrituximabt regulatory cells |
| spellingShingle | A V Torgashina Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab Научно-практическая ревматология systemic lupus erythematosus rituximab t regulatory cells |
| title | Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab |
| title_full | Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab |
| title_fullStr | Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab |
| title_full_unstemmed | Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab |
| title_short | Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab |
| title_sort | relationship of t regulatory cells content activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab |
| topic | systemic lupus erythematosus rituximab t regulatory cells |
| url | https://rsp.mediar-press.net/rsp/article/view/590 |
| work_keys_str_mv | AT avtorgashina relationshipoftregulatorycellscontentactivityandserumautoantibodieslevelinpatientswithsystemiclupuserythematosusreceivingrituximab |